89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Akero raised to Buy at Bank of America after liver drug data
Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.